DUBLIN–(BUSINESS WIRE)–The “Axillary Hyperhidrosis (Dermatology) – Drugs In Development, 2021” report has been added to ResearchAndMarkets.com’s offering.
Axillary Hyperhidrosis – Drugs In Development, 2021, provides an overview of the Axillary Hyperhidrosis (Dermatology) pipeline landscape.
Axillary hyperhidrosis also referred to as excessive underarm sweating. Excessive sweating in the affected area is caused by over activity of the nerves linked to the sweat glands. Specifically, acetylcholine, a chemical in the body that transmits nerve signals, is released from nerve endings and stimulates secretion of sweat. The condition most frequently develops in adolescence or young adulthood. Treatment includes anticholinergic drugs, surgery and antiperspirants.
Report Highlights
Axillary Hyperhidrosis – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Axillary Hyperhidrosis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Axillary Hyperhidrosis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Axillary Hyperhidrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 4, 1, 1 and 2 respectively.
Axillary Hyperhidrosis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Axillary Hyperhidrosis (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Axillary Hyperhidrosis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Axillary Hyperhidrosis (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Axillary Hyperhidrosis (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Axillary Hyperhidrosis (Dermatology)
Key Topics Covered:
Introduction
Axillary Hyperhidrosis – Overview
- Axillary Hyperhidrosis – Therapeutics Development
Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
Axillary Hyperhidrosis – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
Axillary Hyperhidrosis – Companies Involved in Therapeutics Development
- Brickell Biotech Inc
- DelNova Inc
- Dermata Therapeutics Inc
- Dermavant Sciences Inc
- Dermira Inc
- Dr. August Wolff GmbH & Co KG Arzneimittel
- Medytox Inc
- Revance Therapeutics Inc
Axillary Hyperhidrosis – Drug Profiles
- (oxybutynin + pilocarpine)
- DMT-410
- glycopyrrolate
- glycopyrronium tosylate
- nivobotulinumtoxin A
- onabotulinumtoxinA biosimilar
- ReViVox –
- sofpironium bromide
Axillary Hyperhidrosis – Dormant Projects
Axillary Hyperhidrosis – Discontinued Products
Axillary Hyperhidrosis – Product Development Milestones
Featured News & Press Releases
- Jun 29, 2021: Brickell Biotech announces final patient completed in first U.S. phase 3 pivotal clinical study and patient enrollment completed in second U.S. phase 3 pivotal clinical study of Sofpironium Bromide Gel, 15% for the treatment of primary axillary hyperhidrosis
- Jun 24, 2021: Brickell Biotech announces initiation of a phase 1 study of Sofpironium Bromide Gel in primary palmoplantar hyperhidrosis patients by its development partner, Kaken Pharmaceutical in Japan
- Jun 01, 2021: Brickell Biotech announces publication of Japan phase 3 long-term safety and efficacy study results for Sofpironium Bromide Gel, 5% (ECCLOCK) in the Journal of Dermatology
- Apr 27, 2021: Brickell Biotech completes patient enrollment in U.S. phase 3 pivotal Cardigan I study of Sofpironium Bromide Gel, 15% for the treatment of primary axillary hyperhidrosis
- Apr 23, 2021: Brickell Biotech reports results from U.S. phase 3 open-label, long-term safety study on chronic use of sofpironium bromide gel as a potential treatment for primary axillary hyperhidrosis
- Apr 16, 2021: Brickell Biotech announces presentation of US phase 3 open-label long-term safety study results for Sofpironium Bromide Gel at the Late-Breaking Research Program during American Academy of Dermatology’s 2021 VMX
- Apr 15, 2021: Brickell Biotech announces publication of its HDSM-Ax patient reported outcome scale validation results in the Journal of Drugs in Dermatology
- Mar 05, 2021: Brickell Biotech to host key opinion leader webinar on the hyperhidrosis market
- Jan 19, 2021: Brickell Biotech announces publication of Japan pivotal phase 3 study results for Sofpironium Bromide Gel, 5% (ECCLOCK) in the Journal of Dermatology
- Dec 07, 2020: Brickell Biotech doses first patient in second U.S. pivotal phase 3 clinical study
- Nov 18, 2020: Brickell Biotech announces launch date for sofpironium bromide gel, 5% (ECCLOCK) in Japan by its development partner, Kaken Pharmaceutical
- Oct 06, 2020: Brickell Biotech announces initiation of U.S. phase 3 program evaluating sofpironium bromide gel, 15% for the treatment of Primary Axillary Hyperhidrosis
- Sep 25, 2020: Brickell Biotech announces approval of sofpironium bromide gel, 5% in Japan for treatment of primary axillary hyperhidrosis received by its development partner, Kaken Pharmaceutical
- Aug 31, 2020: Brickell Biotech announces issuance of new composition of matter patent on Sofpironium Bromide by the Japanese Patent Office
- Jun 15, 2020: Confirmatory phase 3 study of BBI-4000 meet primary endpoint- Announcement at the 119th Annual Meeting of the Japanese Dermatological Association and the 2020 Annual Meeting of American Academy of Dermatology
Appendix
For more information about this report visit https://www.researchandmarkets.com/r/klxxf5
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900